Antibioticos do Brasil

Antibióticos do Brasil (ABL) is a leading Brazilian pharmaceutical company specializing in the development and large-scale manufacturing of injectable antibiotics. Established in 2003 following the acquisition of Eli Lilly's manufacturing site in Cosmópolis, the company is a subsidiary of the Italian ACS Dobfar group. ABL focuses on critical care therapies, including cephalosporins, carbapenems, and penicillins, serving both the domestic Brazilian market and international clients. The company operates high-capacity GMP-certified facilities and provides contract development and manufacturing services (CDMO) for sterile injectable products. Its operations are vital for the supply of essential medicines to hospitals across Latin America.